Gene:
VEGFA
vascular endothelial growth factor A

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


last updated 01/14/2014

1. FDA Label for regorafenib and EGFR,KRAS,VEGFA

Informative PGx

Summary

The FDA-approved drug label for regorafenib (Stivarga) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were KRAS wild type, an anti-EGFR therapy. The label does not specifically mention any form of genetic testing. This drug-biomarker pair was previously in the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" but has subsequently been removed.

Annotation

Regorafenib (Stivarga) is indicated for patients with metastatic colorectal cancer, or locally advanced, unresectable or metastatic gastrointestinal stromal tumors.

Excerpts from the regorafenib (Stivarga) drug label:

Stivarga® is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions...In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of...VEGFR1, VEGFR2, VEGFR3...at concentrations of regorafenib that have been achieved clinically.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the regorafenib drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Colorectal Neoplasms
    • Indications & usage section, Adverse reactions section, Clinical studies section
    • source: U.S. Food and Drug Administration
  • CYP2B6
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • CYP2C19
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • CYP2C8
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • CYP2C9
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • CYP3A4
    • metabolism/PK, Drug interactions section, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • EGFR
    • other, Indications & usage section
    • source: U.S. Food and Drug Administration
  • FLT1
    • other, Indications & usage section, Clinical pharmacology section, Warnings and precautions section
    • source: U.S. Food and Drug Administration
  • FLT4
    • other, Indications & usage section, Clinical pharmacology section, Warnings and precautions section
    • source: U.S. Food and Drug Administration
  • KDR
    • other, Indications & usage section, Clinical pharmacology section, Warnings and precautions section
    • source: U.S. Food and Drug Administration
  • KRAS
    • other, Indications & usage section, Clinical studies section
    • source: U.S. Food and Drug Administration
  • UGT1A1
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • UGT1A9
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for VEGFA

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA H1 N/A N/A N/A
No VIP available No VIP available VA H2 N/A N/A N/A
No VIP available No VIP available VA H3 N/A N/A N/A
No VIP available No VIP available VA H4 N/A N/A N/A
No VIP available No VIP available VA H5 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1005230 NC_000006.11:g.43736496T>C, NC_000006.12:g.43768759T>C, NG_008732.1:g.3544T>C, NM_001025366.2:c.-1948T>C, NM_001025367.2:c.-1948T>C, NM_001025368.2:c.-1948T>C, NM_001025369.2:c.-1948T>C, NM_001025370.2:c.-1948T>C, NM_001033756.2:c.-1948T>C, NM_001171622.1:c.-1948T>C, NM_001171623.1:c.-2488T>C, NM_001171624.1:c.-2488T>C, NM_001171625.1:c.-2488T>C, NM_001171626.1:c.-2488T>C, NM_001171627.1:c.-2488T>C, NM_001171628.1:c.-2488T>C, NM_001171629.1:c.-2488T>C, NM_001171630.1:c.-2488T>C, NM_001204384.1:c.-2488T>C, NM_001204385.1:c.-1948T>C, NM_001317010.1:c.-2488T>C, NM_003376.5:c.-1948T>C, rs2782257, rs36208052, rs61708505
T > C
SNP
No VIP available No Clinical Annotations available VA
rs10434 NC_000006.11:g.43753212A>G, NC_000006.12:g.43785475A>G, NG_008732.1:g.20260A>G, NM_001025366.2:c.*913A>G, NM_001025367.2:c.*913A>G, NM_001025368.2:c.*913A>G, NM_001025369.2:c.*929A>G, NM_001025370.2:c.*913A>G, NM_001033756.2:c.*847A>G, NM_001171622.1:c.*913A>G, NM_001171623.1:c.*913A>G, NM_001171624.1:c.*913A>G, NM_001171625.1:c.*913A>G, NM_001171626.1:c.*913A>G, NM_001171627.1:c.*929A>G, NM_001171628.1:c.*913A>G, NM_001171629.1:c.*847A>G, NM_001171630.1:c.*913A>G, NM_001204384.1:c.*913A>G, NM_001204385.1:c.*913A>G, NM_001287044.1:c.*913A>G, NM_001317010.1:c.*847A>G, NM_003376.5:c.*913A>G, XM_005249363.1:c.*913A>G, rs3173233, rs60316096
A > G
SNP
No VIP available CA VA
rs13207351 NC_000006.11:g.43737794A>G, NC_000006.12:g.43770057A>G, NG_008732.1:g.4842A>G, NM_001025366.2:c.-650A>G, NM_001025367.2:c.-650A>G, NM_001025368.2:c.-650A>G, NM_001025369.2:c.-650A>G, NM_001025370.2:c.-650A>G, NM_001033756.2:c.-650A>G, NM_001171622.1:c.-650A>G, NM_001171623.1:c.-1190A>G, NM_001171624.1:c.-1190A>G, NM_001171625.1:c.-1190A>G, NM_001171626.1:c.-1190A>G, NM_001171627.1:c.-1190A>G, NM_001171628.1:c.-1190A>G, NM_001171629.1:c.-1190A>G, NM_001171630.1:c.-1190A>G, NM_001204384.1:c.-1190A>G, NM_001204385.1:c.-650A>G, NM_001287044.1:c.-2063A>G, NM_001317010.1:c.-1190A>G, NM_003376.5:c.-650A>G, XM_005249363.1:c.-2063A>G, rs36208387, rs57802586
A > G
SNP
No VIP available CA VA
rs144854329 NC_000006.11:g.43736416_43736433del18, NC_000006.12:g.43768679_43768696del18, NG_008732.1:g.3464_3481del18, NM_001025366.2:c.-2028_-2011del, NM_001025366.2:c.-2028_-2011del18, NM_001025367.2:c.-2028_-2011del, NM_001025367.2:c.-2028_-2011del18, NM_001025368.2:c.-2028_-2011del, NM_001025368.2:c.-2028_-2011del18, NM_001025369.2:c.-2028_-2011del, NM_001025369.2:c.-2028_-2011del18, NM_001025370.2:c.-2028_-2011del, NM_001025370.2:c.-2028_-2011del18, NM_001033756.2:c.-2028_-2011del, NM_001033756.2:c.-2028_-2011del18, NM_001171622.1:c.-2028_-2011del, NM_001171622.1:c.-2028_-2011del18, NM_001171623.1:c.-2568_-2551del, NM_001171623.1:c.-2568_-2551del18, NM_001171624.1:c.-2568_-2551del, NM_001171624.1:c.-2568_-2551del18, NM_001171625.1:c.-2568_-2551del, NM_001171625.1:c.-2568_-2551del18, NM_001171626.1:c.-2568_-2551del, NM_001171626.1:c.-2568_-2551del18, NM_001171627.1:c.-2568_-2551del, NM_001171627.1:c.-2568_-2551del18, NM_001171628.1:c.-2568_-2551del, NM_001171628.1:c.-2568_-2551del18, NM_001171629.1:c.-2568_-2551del, NM_001171629.1:c.-2568_-2551del18, NM_001171630.1:c.-2568_-2551del, NM_001171630.1:c.-2568_-2551del18, NM_001204384.1:c.-2568_-2551del, NM_001204384.1:c.-2568_-2551del18, NM_001204385.1:c.-2028_-2011del, NM_001204385.1:c.-2028_-2011del18, NM_001317010.1:c.-2568_-2551del, NM_001317010.1:c.-2568_-2551del18, NM_003376.5:c.-2028_-2011del, NM_003376.5:c.-2028_-2011del18
GGTCCCACTCTTCCCACA > -
indel
No VIP available CA VA
rs1570360 NC_000006.11:g.43737830A>G, NC_000006.12:g.43770093A>G, NG_008732.1:g.4878A>G, NM_001025366.2:c.-614A>G, NM_001025367.2:c.-614A>G, NM_001025368.2:c.-614A>G, NM_001025369.2:c.-614A>G, NM_001025370.2:c.-614A>G, NM_001033756.2:c.-614A>G, NM_001171622.1:c.-614A>G, NM_001171623.1:c.-1154A>G, NM_001171624.1:c.-1154A>G, NM_001171625.1:c.-1154A>G, NM_001171626.1:c.-1154A>G, NM_001171627.1:c.-1154A>G, NM_001171628.1:c.-1154A>G, NM_001171629.1:c.-1154A>G, NM_001171630.1:c.-1154A>G, NM_001204384.1:c.-1154A>G, NM_001204385.1:c.-614A>G, NM_001287044.1:c.-2027A>G, NM_001317010.1:c.-1154A>G, NM_003376.5:c.-614A>G, XM_005249363.1:c.-2027A>G, rs36208386, rs58036053
A > G
SNP
No VIP available CA VA
rs2010963 NC_000006.11:g.43738350C>G, NC_000006.12:g.43770613C>G, NG_008732.1:g.5398C>G, NM_001025366.2:c.-94C>G, NM_001025367.2:c.-94C>G, NM_001025368.2:c.-94C>G, NM_001025369.2:c.-94C>G, NM_001025370.2:c.-94C>G, NM_001033756.2:c.-94C>G, NM_001171622.1:c.-94C>G, NM_001171623.1:c.-634C>G, NM_001171624.1:c.-634C>G, NM_001171625.1:c.-634C>G, NM_001171626.1:c.-634C>G, NM_001171627.1:c.-634C>G, NM_001171628.1:c.-634C>G, NM_001171629.1:c.-634C>G, NM_001171630.1:c.-634C>G, NM_001204384.1:c.-634C>G, NM_001204385.1:c.-94C>G, NM_001287044.1:c.-1507C>G, NM_001317010.1:c.-634C>G, NM_003376.5:c.-94C>G, XM_005249363.1:c.-1507C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2146323 NC_000006.11:g.43745095C>A, NC_000006.12:g.43777358C>A, NG_008732.1:g.12143C>A, NM_001025366.2:c.659-111C>A, NM_001025367.2:c.659-111C>A, NM_001025368.2:c.659-111C>A, NM_001025369.2:c.659-111C>A, NM_001025370.2:c.659-111C>A, NM_001033756.2:c.659-111C>A, NM_001171622.1:c.659-111C>A, NM_001171623.1:c.119-111C>A, NM_001171624.1:c.119-111C>A, NM_001171625.1:c.119-111C>A, NM_001171626.1:c.119-111C>A, NM_001171627.1:c.119-111C>A, NM_001171628.1:c.119-111C>A, NM_001171629.1:c.119-111C>A, NM_001171630.1:c.119-111C>A, NM_001204384.1:c.119-111C>A, NM_001204385.1:c.659-111C>A, NM_001287044.1:c.35-111C>A, NM_001317010.1:c.119-111C>A, NM_003376.5:c.659-111C>A, XM_005249363.1:c.35-111C>A
C > A
SNP
No VIP available CA VA
rs25648 NC_000006.11:g.43738977C>T, NC_000006.12:g.43771240C>T, NG_008732.1:g.6025C>T, NM_001025366.2:c.534C>T, NM_001025367.2:c.534C>T, NM_001025368.2:c.534C>T, NM_001025369.2:c.534C>T, NM_001025370.2:c.534C>T, NM_001033756.2:c.534C>T, NM_001171622.1:c.534C>T, NM_001171623.1:c.-7C>T, NM_001171624.1:c.-7C>T, NM_001171625.1:c.-7C>T, NM_001171626.1:c.-7C>T, NM_001171627.1:c.-7C>T, NM_001171628.1:c.-7C>T, NM_001171629.1:c.-7C>T, NM_001171630.1:c.-7C>T, NM_001204384.1:c.-7C>T, NM_001204385.1:c.534C>T, NM_001287044.1:c.-880C>T, NM_001317010.1:c.-7C>T, NM_003376.5:c.534C>T, NP_001020537.2:p.Ser178=, NP_001020538.2:p.Ser178=, NP_001020539.2:p.Ser178=, NP_001020540.2:p.Ser178=, NP_001020541.2:p.Ser178=, NP_001028928.1:p.Ser178=, NP_001165093.1:p.Ser178=, NP_001191314.1:p.Ser178=, NP_003367.4:p.Ser178=, XM_005249363.1:c.-880C>T
C > T
SNP
S178S
No VIP available CA VA
rs3025000 NC_000006.11:g.43746169C>T, NC_000006.12:g.43778432C>T, NG_008732.1:g.13217C>T, NM_001025366.2:c.856-28C>T, NM_001025367.2:c.856-28C>T, NM_001025368.2:c.856-28C>T, NM_001025369.2:c.856-28C>T, NM_001025370.2:c.856-28C>T, NM_001033756.2:c.856-28C>T, NM_001171622.1:c.856-28C>T, NM_001171623.1:c.316-28C>T, NM_001171624.1:c.316-28C>T, NM_001171625.1:c.316-28C>T, NM_001171626.1:c.316-28C>T, NM_001171627.1:c.316-28C>T, NM_001171628.1:c.316-28C>T, NM_001171629.1:c.316-28C>T, NM_001171630.1:c.316-28C>T, NM_001204384.1:c.316-28C>T, NM_001204385.1:c.856-28C>T, NM_001287044.1:c.232-28C>T, NM_001317010.1:c.316-28C>T, NM_003376.5:c.856-28C>T, XM_005249363.1:c.232-28C>T, rs3730318, rs60421248
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3025030 NC_000006.11:g.43750587G>C, NC_000006.12:g.43782850G>C, NG_008732.1:g.17635G>C, NM_001025366.2:c.1217+763G>C, NM_001025367.2:c.1148+763G>C, NM_001025368.2:c.1094+763G>C, NM_001025369.2:c.1059+798G>C, NM_001025370.2:c.963-1691G>C, NM_001033756.2:c.1094+763G>C, NM_001171622.1:c.933-1691G>C, NM_001171623.1:c.677+763G>C, NM_001171624.1:c.626+763G>C, NM_001171625.1:c.608+763G>C, NM_001171626.1:c.554+763G>C, NM_001171627.1:c.519+798G>C, NM_001171628.1:c.423-1691G>C, NM_001171629.1:c.554+763G>C, NM_001171630.1:c.393-1691G>C, NM_001204384.1:c.495-1691G>C, NM_001204385.1:c.1035-1691G>C, NM_001287044.1:c.470+763G>C, NM_001317010.1:c.554+763G>C, NM_003376.5:c.1166+763G>C, XM_005249363.1:c.470+763G>C, rs16896816, rs3799959, rs61356923
G > C
SNP
No VIP available No Clinical Annotations available VA
rs3025033 NC_000006.11:g.43751075A>G, NC_000006.12:g.43783338A>G, NG_008732.1:g.18123A>G, NM_001025366.2:c.1218-1203A>G, NM_001025367.2:c.1149-1203A>G, NM_001025368.2:c.1095-1203A>G, NM_001025369.2:c.1060-1203A>G, NM_001025370.2:c.963-1203A>G, NM_001033756.2:c.1094+1251A>G, NM_001171622.1:c.933-1203A>G, NM_001171623.1:c.678-1203A>G, NM_001171624.1:c.627-1203A>G, NM_001171625.1:c.609-1203A>G, NM_001171626.1:c.555-1203A>G, NM_001171627.1:c.520-1203A>G, NM_001171628.1:c.423-1203A>G, NM_001171629.1:c.554+1251A>G, NM_001171630.1:c.393-1203A>G, NM_001204384.1:c.495-1203A>G, NM_001204385.1:c.1035-1203A>G, NM_001287044.1:c.471-1203A>G, NM_001317010.1:c.555-1203A>G, NM_003376.5:c.1167-1203A>G, XM_005249363.1:c.471-1203A>G, rs3778502, rs59547322
A > G
SNP
No VIP available CA VA
rs3025039 NC_000006.11:g.43752536C>T, NC_000006.12:g.43784799C>T, NG_008732.1:g.19584C>T, NM_001025366.2:c.*237C>T, NM_001025367.2:c.*237C>T, NM_001025368.2:c.*237C>T, NM_001025369.2:c.*253C>T, NM_001025370.2:c.*237C>T, NM_001033756.2:c.*171C>T, NM_001171622.1:c.*237C>T, NM_001171623.1:c.*237C>T, NM_001171624.1:c.*237C>T, NM_001171625.1:c.*237C>T, NM_001171626.1:c.*237C>T, NM_001171627.1:c.*253C>T, NM_001171628.1:c.*237C>T, NM_001171629.1:c.*171C>T, NM_001171630.1:c.*237C>T, NM_001204384.1:c.*237C>T, NM_001204385.1:c.*237C>T, NM_001287044.1:c.*237C>T, NM_001317010.1:c.*171C>T, NM_003376.5:c.*237C>T, XM_005249363.1:c.*237C>T, rs11575898
C > T
SNP
No VIP available CA VA
rs3025040
C > T
SNP
No VIP available No Clinical Annotations available VA
rs35569394 unknown
No VIP available CA VA
rs35864111 NC_000006.11:g.43736537_43736538insG, NC_000006.12:g.43768800_43768801insG, NG_008732.1:g.3585_3586insG, NM_001025366.2:c.-1907_-1906insG, NM_001025367.2:c.-1907_-1906insG, NM_001025368.2:c.-1907_-1906insG, NM_001025369.2:c.-1907_-1906insG, NM_001025370.2:c.-1907_-1906insG, NM_001033756.2:c.-1907_-1906insG, NM_001171622.1:c.-1907_-1906insG, NM_001171623.1:c.-2447_-2446insG, NM_001171624.1:c.-2447_-2446insG, NM_001171625.1:c.-2447_-2446insG, NM_001171626.1:c.-2447_-2446insG, NM_001171627.1:c.-2447_-2446insG, NM_001171628.1:c.-2447_-2446insG, NM_001171629.1:c.-2447_-2446insG, NM_001171630.1:c.-2447_-2446insG, NM_001204384.1:c.-2447_-2446insG, NM_001204385.1:c.-1907_-1906insG, NM_001317010.1:c.-2447_-2446insG, NM_003376.5:c.-1907_-1906insG, rs144735486, rs36208053, rs369394745, rs372156176
- > G
indel
No VIP available CA VA
rs6900017 NC_000006.11:g.43758485C>T, NC_000006.12:g.43790748C>T, rs58250555
C > T
SNP
No VIP available No Clinical Annotations available VA
rs699946 NC_000006.11:g.43732669A>G, NC_000006.12:g.43764932A>G, rs60848875
A > G
SNP
No VIP available CA VA
rs699947 NC_000006.11:g.43736389A>C, NC_000006.12:g.43768652A>C, NG_008732.1:g.3437A>C, NM_001025366.2:c.-2055A>C, NM_001025367.2:c.-2055A>C, NM_001025368.2:c.-2055A>C, NM_001025369.2:c.-2055A>C, NM_001025370.2:c.-2055A>C, NM_001033756.2:c.-2055A>C, NM_001171622.1:c.-2055A>C, NM_001171623.1:c.-2595A>C, NM_001171624.1:c.-2595A>C, NM_001171625.1:c.-2595A>C, NM_001171626.1:c.-2595A>C, NM_001171627.1:c.-2595A>C, NM_001171628.1:c.-2595A>C, NM_001171629.1:c.-2595A>C, NM_001171630.1:c.-2595A>C, NM_001204384.1:c.-2595A>C, NM_001204385.1:c.-2055A>C, NM_001317010.1:c.-2595A>C, NM_003376.5:c.-2055A>C, rs1310065, rs36208051, rs61399354
A > C
SNP
No VIP available No Clinical Annotations available VA
rs7664413 NC_000004.11:g.177608707C>T, NC_000004.12:g.176687553C>T, NG_034216.1:g.110193G>A, NM_005429.4:c.812-33G>A, XR_939498.1:n.260+7803C>T, XR_939499.1:n.209+17844C>T, rs58304891
C > T
SNP
No VIP available CA VA
rs833061 NC_000006.11:g.43737486C>T, NC_000006.12:g.43769749C>T, NG_008732.1:g.4534C>T, NM_001025366.2:c.-958C>T, NM_001025367.2:c.-958C>T, NM_001025368.2:c.-958C>T, NM_001025369.2:c.-958C>T, NM_001025370.2:c.-958C>T, NM_001033756.2:c.-958C>T, NM_001171622.1:c.-958C>T, NM_001171623.1:c.-1498C>T, NM_001171624.1:c.-1498C>T, NM_001171625.1:c.-1498C>T, NM_001171626.1:c.-1498C>T, NM_001171627.1:c.-1498C>T, NM_001171628.1:c.-1498C>T, NM_001171629.1:c.-1498C>T, NM_001171630.1:c.-1498C>T, NM_001204384.1:c.-1498C>T, NM_001204385.1:c.-958C>T, NM_001317010.1:c.-1498C>T, NM_003376.5:c.-958C>T, rs36208046, rs60746584
C > T
SNP
No VIP available No Clinical Annotations available VA
rs833062 NC_000006.11:g.43737529T>C, NC_000006.12:g.43769792T>C, NG_008732.1:g.4577T>C, NM_001025366.2:c.-915T>C, NM_001025367.2:c.-915T>C, NM_001025368.2:c.-915T>C, NM_001025369.2:c.-915T>C, NM_001025370.2:c.-915T>C, NM_001033756.2:c.-915T>C, NM_001171622.1:c.-915T>C, NM_001171623.1:c.-1455T>C, NM_001171624.1:c.-1455T>C, NM_001171625.1:c.-1455T>C, NM_001171626.1:c.-1455T>C, NM_001171627.1:c.-1455T>C, NM_001171628.1:c.-1455T>C, NM_001171629.1:c.-1455T>C, NM_001171630.1:c.-1455T>C, NM_001204384.1:c.-1455T>C, NM_001204385.1:c.-915T>C, NM_001317010.1:c.-1455T>C, NM_003376.5:c.-915T>C
T > C
SNP
No VIP available CA VA
rs833069 NC_000006.11:g.43742579T>C, NC_000006.12:g.43774842T>C, NG_008732.1:g.9627T>C, NM_001025366.2:c.658+450T>C, NM_001025367.2:c.658+450T>C, NM_001025368.2:c.658+450T>C, NM_001025369.2:c.658+450T>C, NM_001025370.2:c.658+450T>C, NM_001033756.2:c.658+450T>C, NM_001171622.1:c.658+450T>C, NM_001171623.1:c.118+450T>C, NM_001171624.1:c.118+450T>C, NM_001171625.1:c.118+450T>C, NM_001171626.1:c.118+450T>C, NM_001171627.1:c.118+450T>C, NM_001171628.1:c.118+450T>C, NM_001171629.1:c.118+450T>C, NM_001171630.1:c.118+450T>C, NM_001204384.1:c.118+450T>C, NM_001204385.1:c.658+450T>C, NM_001287044.1:c.34+450T>C, NM_001317010.1:c.118+450T>C, NM_003376.5:c.658+450T>C, XM_005249363.1:c.34+450T>C, rs1612658, rs3778495, rs386616780, rs61226611
T > C
SNP
No VIP available CA VA
rs879825 NC_000006.11:g.43763814A>G, NC_000006.12:g.43796077A>G, XR_926833.1:n.-1044A>G, rs57569840
A > G
SNP
No VIP available CA VA
rs9369421 NC_000006.11:g.43762122T>C, NC_000006.12:g.43794385T>C, rs52800915
T > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  VEGF
Alternate Symbols:  VEGF-A; VPF
PharmGKB Accession Id: PA37302

Details

Cytogenetic Location: chr6 : p21.1 - p21.1
GP mRNA Boundary: chr6 : 43737946 - 43754224
GP Gene Boundary: chr6 : 43727946 - 43757224
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Haplotype Overview

Haplotypes derived from [Article:26002049].

Source: PharmGKB [Article:26002049]

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Celecoxib Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of celecoxib and candidate genes interacting with celecoxib and involved in the regulation of cell cycle, apoptosis and angiogenesis by celecoxib.
  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

Curated Information ?

Curated Information ?

Curated Information ?

Publications related to VEGFA: 73

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. Pharmacogenomics. 2016. Agarwal Aniruddha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. Pharmacogenomics. 2016. He Ruo-Hui, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. International journal of cancer. Journal international du cancer. 2015. Hein Alexander, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics. 2015. Rollin Jérôme, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Scientific reports. 2016. Qin Chao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. The pharmacogenomics journal. 2015. He Y J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. European journal of clinical pharmacology. 2015. Oliveira-Paula G H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer chemotherapy and pharmacology. 2015. Panoilia Eirini, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of VEGFA gene polymorphisms and VEGFA plasma levels with spontaneous preterm birth. Pharmacogenetics and genomics. 2015. Langmia Immaculate Mbongo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer. 2014. Derosa Lisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic markers of recurrence in colorectal cancer. Pharmacogenomics. 2015. Smolle Maria Anna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis. PloS one. 2015. Wang Lei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2014. Patel Jai N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. International journal of cancer. 2014. Scartozzi Mario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of erectile dysfunction: navigating into uncharted waters. Pharmacogenomics. 2014. Lacchini Riccardo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration. Retina (Philadelphia, Pa.). 2014. Park Un Chul, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology. 2014. Miyake Masahiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics. 2013. Scartozzi Mario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update. Pharmacogenomics. 2013. Eng Lawson, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. Retina (Philadelphia, Pa.). 2013. Hautamäki Asta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel. The pharmacogenomics journal. 2013. Koutras A K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. British journal of cancer. 2013. Orlandi P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Investigational new drugs. 2013. Infante Jeffrey R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics. 2013. Lazzeri Stefano, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2013. Lee Joo Ho, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013. Abedi Farshad, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Molecular vision. 2013. Chang Woohyok, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology. 2012. Smailhodzic Dzenita, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clinical pharmacology and therapeutics. 2012. Eechoute K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012. Eng Lawson, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction. The pharmacogenomics journal. 2012. Lacchini R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics. 2012. Agosta Elisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics. 2012. Tian Jun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. The pharmacogenomics journal. 2012. Pohl A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leukemia research. 2011. Cibeira María Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. The pharmacogenomics journal. 2011. Koutras A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF -460T ¿ C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. The pharmacogenomics journal. 2011. Chen M-H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Argiris Athanassios, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. The pharmacogenomics journal. 2011. Hansen T F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology. 2010. Galan Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. The pharmacogenomics journal. 2010. Ho-Pun-Cheung A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Lindauer A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vascular endothelial growth factor pathway. Pharmacogenetics and genomics. 2010. Maitland Michael L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics. 2009. Coltelli Luigi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics. 2009. Formento Jean-Louis, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (New York, N.Y.). 2009. Bostrom Jenny, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A stress-responsive RNA switch regulates VEGFA expression. Nature. 2009. Ray Partho Sarothi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC cancer. 2009. Glaysher Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel single nucleotide polymorphism of the VEGF gene as a risk predictor for gastroduodenal ulcers. Journal of gastroenterology and hepatology. 2008. Kim Yong Seok, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Schultheis Anne M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008. Kleinman Mark E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF inhibition and renal thrombotic microangiopathy. The New England journal of medicine. 2008. Eremina Vera, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of EGFR and VEGF inhibition. Drug discovery today. 2007. Pander Jan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Ito Noriyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics. 2007. Vincenzi Bruno, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS genetics. 2007. García-Closas Montserrat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of sudden infant death syndrome with VEGF and IL-6 gene polymorphisms. Human immunology. 2006. Dashash Mayssoon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and genomics. 2006. Zhang Wu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vascular endothelial growth factor gene variability is associated with increased risk for AD. Annals of neurology. 2005. Del Bo Roberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer research. 2004. Blázquez Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer research. 2004. Wei Daoyan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. The Journal of cell biology. 2003. Hood John D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. The New England journal of medicine. 2003. Yang James C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature medicine. 2003. Qi Jian Hua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002. Stopeck Alison, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. The Journal of biological chemistry. 2000. Radisavljevic Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. The American journal of physiology. 1999. Wu H M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998. Soker S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. The Journal of clinical investigation. 1997. Papapetropoulos A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer research. 1997. Presta L G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proceedings of the National Academy of Sciences of the United States of America. 1993. Kendall R L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochemical and biophysical research communications. 1992. Terman B I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (New York, N.Y.). 1992. de Vries C, et al. PubMed